Patrick McCann, MD
Advanced Heart Failure and Transplant Cardiology · Columbia, SCNPI 1487850780
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Abbott at 42.4% of the total. Among advanced heart failure and transplant cardiology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,408 payments — averaging $410.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$245K
- Cvrx, Inc.$153K
- AstraZeneca$119K
- Novartis$23K
- Johnson & Johnson$12K
- Lexicon Pharmaceuticals, Inc.$10K
- plus $15K from 27 others
Across 40 payments — averaging $19,983 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$622K
- Novartis$70K
- American Regent$40K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29K
- Medtronic$24K
- Actelion Pharmaceuticals, Ltd$10K
- plus $6K from 1 others
What the payments were for
- Consulting fees$320,36155%
- Speaking & faculty fees$143,06525%
- Travel & lodging$81,64214%
- Food & beverage$33,5216%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 631 | $245,156 |
| Cvrx, Inc. | 171 | $153,222 |
| AstraZeneca | 152 | $119,431 |
| Novartis | 91 | $23,476 |
| Johnson & Johnson | 23 | $11,757 |
| Lexicon Pharmaceuticals, Inc. | 12 | $10,175 |
| Daxor Corporation | 5 | $4,066 |
| Ancora Heart, Inc. | 15 | $2,328 |
| Boston Scientific | 53 | $1,873 |
| Medtronic(2 entities) | 16 | $1,227 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $977 |
| Alnylam Pharmaceuticals Inc. | 37 | $670 |
| Abiomed | 12 | $625 |
| Pfizer | 24 | $586 |
| Actelion Pharmaceuticals US, Inc. | 20 | $441 |
| Merck | 24 | $435 |
| Boehringer Ingelheim | 22 | $415 |
| Impulse Dynamics (USA) Inc. | 15 | $388 |
| Philips North America LLC | 2 | $307 |
| Nuwellis, Inc. | 9 | $242 |
| Scpharmaceuticals Inc. | 11 | $189 |
| Novo Nordisk | 8 | $145 |
| Bayer | 7 | $120 |
| Nobel Biocare USA | 1 | $72 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Amgen | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Vifor Pharma, Inc. | 2 | $39 |
| Livanova USA, Inc. | 2 | $28 |
| Recor Medical Inc | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Endotronix, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$150,986
- CARDIOMEMS$130,037
- FARXIGA$117,575
- CardioMEMS HF System$79,390
- ENTRESTO$17,471
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$17,039
- XARELTO$11,399
- Inpefa$10,006
- HeartMate 3 Left Ventricular Assist Device$6,325
- HeartMate 3 Left Ventricular Dev$4,464
- BVA-100$4,000
- AccuCinch$2,035
- AMPLATZER TALISMAN$1,094
- WATCHMAN Access System$375
- (5044) MCOT$307
- LINQ II$270
- Micra$270
- OPTIMIZER$254
- MitraClip System$191
- Advisa$145
How this compares
$578,616 in reported general payments places this provider in the 95th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
See all advanced heart failure and transplant cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 47 | $978,327 |
| EntrestoSacubitril/Valsartan | 305 | $340,970 |
| VyndaqelTafamidis Meglumine | 13 | $292,550 |
| CamzyosMavacamten | 25 | $198,967 |
| FarxigaDapagliflozin Propanediol | 145 | $138,103 |
| JardianceEmpagliflozin | 145 | $136,479 |
| EliquisApixaban | 83 | $64,590 |
| VerquvoVericiguat | 19 | $21,700 |
| XareltoRivaroxaban | 23 | $19,609 |
| BrilintaTicagrelor | 11 | $6,376 |
| Bumetanide | 89 | $3,739 |
| Metoprolol Succinate | 114 | $1,773 |
| Spironolactone | 138 | $1,327 |
| Torsemide | 33 | $936 |
| Carvedilol | 92 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $586 | $1,335,466143 claims |
| NovartisEntresto | $23,476 | $340,970305 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $46 | $198,96725 claims |
| AstraZenecaFarxiga, Brilinta | $119,431 | $144,478156 claims |
| Boehringer IngelheimJardiance | $415 | $136,479145 claims |
| MerckVerquvo | $435 | $21,70019 claims |
| Johnson & JohnsonXarelto | $11,757 | $19,60923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
Other advanced heart failure and transplant cardiology in Columbia
- James AmpaduColumbia$131K
- Cassandra Buto-CollettiColumbia$21K
- Joshua ConeyColumbia$14K
- Barry FeldmanColumbia$12K
- Rebecca NapierColumbia$12K
- Michael RofaelColumbia$11K
- Ryan TedfordCharleston$528K
- Michael ZileCharleston$358K
- Anil PurohitWest Columbia$172K
- Daniel JudgeCharleston$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.